West Pharmaceutical Services (NYSE:WST) Stock Moved Up to "Buy" by Wall Street Zen

Key Points

• Wall Street Zen upgraded West Pharmaceutical Services to “Buy” from “Hold,” joining a broader positive analyst view. Twelve analysts rate the stock Buy and two rate it Hold, for a consensus “Moderate Buy” rating and $409.67 average price target.
• West reported strong quarterly results, with EPS of $2.66 versus the $2.20 consensus and revenue of $874.5 million, up 8.7% year over year. Management also raised its full-year revenue and adjusted EPS guidance.
• Despite improving fundamentals, valuation is a potential risk after the stock’s rally: shares opened at $412.73, near their $438.27 12-month high, while insiders have recently sold shares and the stock trades at a P/E of 46.32.

West Pharmaceutical Services (NYSE:WST - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Sunday, Wall Street Zen reports.

A number of other research firms also recently issued reports on WST. Evercore reissued an "outperform" rating and issued a $425.00 target price on shares of West Pharmaceutical Services in a research report on Monday, July 27th. Citigroup boosted their price objective on shares of West Pharmaceutical Services from $412.00 to $494.00 and gave the company a "buy" rating in a research note on Friday. Weiss Ratings upgraded West Pharmaceutical Services from a "hold (c)" rating to a "hold (c+)" rating in a research note on Friday, August 7th. BNP Paribas Exane assumed coverage on shares of West Pharmaceutical Services in a research report on Monday, July 13th. They set an "outperform" rating and a $447.00 price objective on the stock. Finally, TD Cowen upped their target price on West Pharmaceutical Services from $420.00 to $500.00 and gave the stock a "buy" rating in a research note on Friday. Twelve equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $409.67.

West Pharmaceutical Services Stock Performance

NYSE WST opened at $412.73 on Friday. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The company has a fifty day simple moving average of $367.76 and a 200 day simple moving average of $313.21. The company has a market cap of $29.05 billion, a P/E ratio of 46.32, a PEG ratio of 2.73 and a beta of 1.13. West Pharmaceutical Services has a 12-month low of $223.83 and a 12-month high of $438.27.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.20 by $0.46. West Pharmaceutical Services had a return on equity of 21.78% and a net margin of 18.81%. The business had revenue of $874.50 million during the quarter, compared to the consensus estimate of $827.12 million. During the same quarter in the prior year, the company posted $1.96 earnings per share. West Pharmaceutical Services's revenue was up 8.7% compared to the same quarter last year. Sell-side analysts predict that West Pharmaceutical Services will post 9.46 earnings per share for the current fiscal year.

Insider Transactions at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Annette Favorite sold 8,135 shares of the firm's stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $340.81, for a total value of $2,772,489.35. Following the completion of the sale, the vice president directly owned 16,845 shares in the company, valued at $5,740,944.45. This trade represents a 32.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders have sold 15,659 shares of company stock valued at $5,443,749 over the last ninety days. 0.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On West Pharmaceutical Services

A number of institutional investors have recently added to or reduced their stakes in the company. Addison Advisors LLC purchased a new stake in West Pharmaceutical Services in the second quarter worth approximately $28,000. Avalon Trust Co bought a new position in shares of West Pharmaceutical Services during the 2nd quarter valued at approximately $28,000. Cornerstone Planning Group LLC increased its stake in shares of West Pharmaceutical Services by 90.9% in the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 50 shares in the last quarter. Elevation Wealth Partners LLC raised its position in shares of West Pharmaceutical Services by 1,377.8% during the 2nd quarter. Elevation Wealth Partners LLC now owns 133 shares of the medical instruments supplier's stock valued at $48,000 after purchasing an additional 124 shares during the period. Finally, Raiffeisen Bank International AG raised its position in shares of West Pharmaceutical Services by 95.6% during the 2nd quarter. Raiffeisen Bank International AG now owns 133 shares of the medical instruments supplier's stock valued at $47,000 after purchasing an additional 65 shares during the period. Institutional investors own 93.90% of the company's stock.

Key West Pharmaceutical Services News

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q3 results exceeded expectations: West reported adjusted earnings of $2.66 per share, above the $2.20 consensus estimate, while revenue rose 8.7% year over year to $874.5 million, surpassing the $827.1 million forecast. West Reports Third-Quarter 2026 Results
• Positive Sentiment: Higher 2026 outlook: Management raised full-year revenue guidance to $3.41 billion-$3.42 billion from $3.345 billion-$3.380 billion and lifted adjusted EPS guidance to $9.38-$9.48 from $8.85-$9.05. West Pharmaceutical Services Raises Annual Outlook
• Positive Sentiment: Strong high-value product demand: High-Value Product Components sales increased 19.7% and accounted for 53% of quarterly sales, supporting margin expansion and confidence in the company’s growth mix. West Pharma Q3 Earnings Rise on HVP Strength
• Positive Sentiment: Barclays raised its price target to $500 from $440 and maintained an “overweight” rating, implying additional upside based on the referenced share price. Barclays Raises West Pharmaceutical Price Target
• Neutral Sentiment: Institutional positioning was mixed, with several large funds adding shares while others reduced or exited positions. Recent insider activity also showed sales rather than purchases, though these transactions may not reflect the company’s operating outlook.
• Negative Sentiment: Valuation remains a risk after the rally, with the stock trading at a high earnings multiple. One analysis also cautioned that declining cash flow may leave the shares overvalued if earnings growth moderates. West Stock Could Be Overvalued

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.